TIFFANY TRAN: Open Payments
NPI 1922770551 · ANAHEIM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,759 in 129 payments from 16 companies in 2025. Trend: 2023 $2,148 · 2024 $2,259 · 2025 $2,759
Food & beverage: $2,759
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $511 |
| Otsuka America Pharmaceutical, Inc. | 16 | $372 |
| Janssen Pharmaceuticals, Inc | 10 | $296 |
| Teva Pharmaceuticals USA, Inc. | 13 | $281 |
| E.R. Squibb & Sons, L.L.C. | 11 | $230 |
| Alkermes, Inc. | 12 | $227 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $198 |
| Neurocrine BioSciences, Inc. | 5 | $151 |
| Lundbeck LLC | 6 | $127 |
| Noven Therapeutics, LLC | 6 | $115 |
Products named: VRAYLAR, REXULTI, AUSTEDO XR, INVEGA SUSTENNA, COBENFY, ARISTADA, CAPLYTA, INGREZZA.
Industry payments across CA — which companies pay providers there.
